CNBC: Judge mulls not approving CVS-Aetna agreement

Amy Baxter | | Health Exec | Policy & Regulations

While the $69 billion merger between CVS Health and Aetna has been approved by regulators and cleared by the Department of Justice, a federal judge has raised the prospect of not approving the deal, CNBC reported.

A judge from the U.S. District Court for the District of Columbia noted the deal, which closed Nov. 28, was given a “rubber stamp” treatment by governments, according to CNBC. Despite being approved by other regulators, the agreement between the government and the two companies must also be approved by the court.

According to Aetna, the situation is “commonplace,” CNBC reported.

See the full story below:

US judge raises prospect of not approving CVS-Aetna deal

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

DOJ halts enforcement of updated Mental Health Parity Act
Epic sued over alleged 'scheme to destroy' managed care company
Cardiology groups among the many voices asking Congress not to cut Medicaid
FDA gives AI-powered blood test for obstructive CAD breakthrough device designation
Pentagon ends healthcare for transgender service members
Judge halts some ‘dramatic restructuring’ at HHS as legal challenges pile up

Around the web

Cardiovascular Business
Cardiology groups among the many voices asking Congress not to cut Medicaid

More than 40 U.S. healthcare organizations are urging Congress not to make sweeping Medicaid cuts that could result in approximately 7.6 million Americans losing health insurance.

Radiology Business
U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.

Radiology Business
Tariffs not enough to make Siemens Healthineers move production or raise prices—yet

The imaging manufacturer expects to spend between $227 million and $340 million on tariff mitigation efforts, leaders said Wednesday.